HIV update 2005: Origins, issues, prospects, and complications

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 1, 2005, Pages 73-78

  Armstrong, Wendey ^a   Calabrese, Leonard ^a   Taege, Alan J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LOW DENSITY LIPOPROTEIN; MICROBICIDE; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL TRIAL; CULTURAL FACTOR; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EPIDEMIC; EPIDEMIOLOGICAL DATA; HEALTH BEHAVIOR; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE PLANNING; HEART INFARCTION; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INSULIN RESISTANCE; LIPID ANALYSIS; LIPODYSTROPHY; LONG TERM CARE; MORBIDITY; MORTALITY; SIDE EFFECT; UNITED STATES; VERTICAL TRANSMISSION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 12744269467     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.1.73     Document Type: Article

References (16)

1. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000; 287:607-614.
2. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. Abstract 416B. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
3. Hightow LB, MacDonald P, Pilcher CD, et al. Transmission on campus: insights from tracking HIV incidence in North Carolina. Abstract 84. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
4. Millet G. Men on the 'down low': more questions than answers. Abstract 83. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
5. Puls RL, Carr A. Practical applications of the HIV lipodystrophy case definition. AIDS Read 2003; 13:480-481, 486-487, 491-493.
6. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
7. McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13:539-542, 559.
8. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263-270. Epub 2003 Dec 18.
9. Moyle GJ. Lipid abnormalities during ART: it's the drug, not the class. AIDS Read 2004; 14:15-16, 20-22.
10. Hruz P, Murata H, Qui H,Mueckler M. Indinavir induces acute reversible peripheral insulin resistance in rats. Diabetes 2002; 51:937-942.
11. Sklar P, Masur H. HIV infection and cardiovascular disease - is there really a link? N Engl J Med 2003; 349:2065-2067.
12. Steinhart CR, Emons MF. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment. AIDS Read 2004; 14:86-90, 93-95.
13. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
14. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
15. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
16. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.